MedTrace Logo

PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment

NCT02618850 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2023-03-24

No results posted yet for this study

Summary

The purpose of this study is to test whether an early metabolic response, measured by PET/CT scan after the first cycle of chemotherapy, is able to predict which patients with advanced CRC have a better prognosis.

Conditions

  • Colorectal Cancer Stage IV

Interventions

PROCEDURE

PET/CT

PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy

DRUG

first-line chemotherapy

as prescribed by oncologist

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Secondo Lastoria, M.D. · National Cancer Institute, Naples

  • Francesco Perrone, M.D., Ph.D · National Cancer Institute Naples, Italy; Director Clinical Trials Unit

  • Ciro Gallo, M.D., Ph.D · Second University of Naples, Italy; Chair of Medical Statistics

  • Luigi Aloj, M.D. · National Cancer Institute, Naples

  • Corradina Caracò, M.D. · National Cancer Institute, Naples

  • Vincenzo Iaffaioli, M.D. · National Cancer Institute, Naples

  • Guglielmo Nasti, M.D. · National Cancer Institute, Naples

  • Antonio Avallone, M.D. · National Cancer Institute, Naples

  • Giovanni Romano, M.D. · National Cancer Institute, Naples

  • Paolo Delrio, M.D. · National Cancer Institute, Naples

  • Francesco Izzo, M.D. · National Cancer Institute, Naples

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618850 on ClinicalTrials.gov